Vor Biopharma (VOR) has jumped onto investors’ radar after strong Phase 3 data for telitacicept in IgA nephropathy, paired with upbeat new Wall Street coverage that frames the drug’s long term ...

In recent months, Vor Biopharma closed a US$424.83 million shelf registration, repriced employee stock options, and reported positive late-stage clinical data for its autoimmune drug candidate ...

Vor Biopharma Inc. (VOR) stock jumped to a high of $12 yesterday, gaining >20%, but as I discovered to my detriment recently, all is not exactly what it seems at the company. In this post I revisit a ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Jason Fernando is a professional investor and writer who enjoys tackling and communicating complex business and financial problems. The market approach is a method for determining the value of an ...

Julia Kagan is a financial/consumer journalist and former senior editor, personal finance, of Investopedia. Andy Smith is a Certified Financial Planner (CFP®), licensed realtor and educator with over ...

IRAEmpire has released a new and updated list of the best crypto IRA companies in the US to help consumers make better-informed decisions. DALLAS, TEXAS / ACCESS Newswire / December 26, 2025 / More Am ...

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Explainer: How to talk to kids about gender equality and stereotypes Explainer: How to talk to kids about gender equality and stereotypes Press release: USD 420 billion annual shortfall blocking ...